Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effect of Purslane Supplementation on Clinical Outcomes, Inflammatory and Antioxidant Markers in Patients With Rheumatoid Arthritis: A Parallel Double-Blinded Randomized Controlled Clinical Trial Publisher Pubmed



Karimi E1 ; Aryaeian N1, 2 ; Akhlaghi M3 ; Abolghasemi J4 ; Fallah S5 ; Heydarian A1 ; Rostami R5 ; Bayat MH1 ; Mahmoudi M3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Nutritional Sciences Research Center, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Clinical Biochemistry, Faculty of Medicine, Iran University of Medical Sciences Tehran, Iran

Source: Phytomedicine Published:2024


Abstract

Background: Rheumatoid arthritis (RA) is an autoimmune disorder that results in joint dysfunction, inflammation, and increased mortality. Hypothesis/Purpose: The aim of this study was to evaluate the efficacy of purslane supplements on clinical outcomes, as well as inflammation and antioxidant markers in patients with RA. Study Design: A double-blinded randomized controlled clinical trial. Methods: In this 12-week trial, 86 participants aged between 20 and 79 were divided into two groups. The intervention group (n = 43) received a 500 mg purslane capsule twice a day, while the control group (n = 43) received a placebo capsule of the same shape and dosage. Results: Seventy-seven patients (37 from the control group and 40 from the purslane group) completed the study. Purslane capsule intake significantly declined visual analog scale (53.38 ± 23.81 vs. 26.25 ± 17.27, p ≤ 0.001), swollen joint count (4.42 ± 3.36 vs. 1.60 ± 1.64, p ≤ 0.001), tender joint count (8.20 ± 5.93 vs. 2.78± 2.15, p ≤ 0.001), High-sensitivity C-reactive protein (p ≤ 0.001), disease activity score (DAS28) (5.17 ± 1.30 vs. 3.48 ± 1.20, p ≤ 0.001) and increased Superoxide dismutase (p = .037), and total antioxidant capacity (p ≤ 0.001) changes. Furthermore, Morning stiffness (p=.002) and Physician Global Assessment (p = .026) significantly decreased in the purslane group compared to the placebo group at the end of the trial. There was a significant decrease in tumor necrosis factor-α (2.885 ± 2.068 vs. 2.330 ± 1.121, p = .046), and erythrocyte sedimentation rate (36.52 ± 20.04 vs. 26.70 ± 22.59, p = .007) levels in the purslane group. Conclusion: Therefore, supplementation with purslane could lead to improved clinical outcomes, and inflammatory and antioxidant indicators in RA patients. © 2024
Related Docs
1. The Effects of Purslane (Portulaca Oleracea) on Glycemic Indices: A Grade-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials, Phytotherapy Research (2023)
2. The Effects of Purslane Consumption on Blood Pressure, Body Weight, Body Mass Index, and Waist Circumference: A Systematic Review and Meta-Analysis of Randomised Controlled, Journal of Nutritional Science (2023)
3. The Effects of Purslane Consumption on Glycemic Control and Oxidative Stress: A Systematic Review and Dose–Response Meta-Analysis, Food Science and Nutrition (2023)